Scott P. France
Research Subjects
Scott P. France has a total of 387 co-authors. Here are the top co-authors by number of shared publications:
- Nicholas John Turner
Department of Chemistry, Manchester Institute of Biotechnology, University of Manchester, 131 Princess Street, Manchester M1 7DN, U.K.
16 shared publications - Simon Berritt
Worldwide Research and Development
9 shared publications - Roger M. Howard
Pfizer (United States)
8 shared publications - Godwin Abazho Aleku
Institute of Pharmaceutical Science King's College London London UK
7 shared publications - Sarah Louise Montgomery
School of Chemistry, University of Manchester, Manchester Institute of Biotechnology, 131 Princess Street, Manchester M1 7DN, UK
7 shared publications - Emma L. McInturff
Groton Laboratories, Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States
6 shared publications
Latest Publications
- 17 June 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (13) , 15045-15091
Synthetic Approaches to the New Drugs Approved During 2024
In 2024, thirty-nine new small molecule drugs were approved worldwide. A brief introduction to each new drug is followed by the synthetic details that highlight the most scalable routes available at the time of publication in patents or primary literature. Structural complexity varies widely across the drugs that are included in the review, as do the methods of synthesis used to access these new drugs.
- 17 June 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (13) , 15045-15091
Synthetic Approaches to the New Drugs Approved During 2024
In 2024, thirty-nine new small molecule drugs were approved worldwide. A brief introduction to each new drug is followed by the synthetic details that highlight the most scalable routes available at the time of publication in patents or primary literature. Structural complexity varies widely across the drugs that are included in the review, as do the methods of synthesis used to access these new drugs.
- Top Cited Papers
- 7 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6798) , 643-647
Biocatalytic cascades enable manufacture of the macrocyclic peptide enlicitide
Historically, many compelling therapeutic targets have been accessible only by injectable biologic drugs. Macrocyclic peptides, such as the proprotein convertase subtilisin/kexin type 9 inhibitor enlicitide for the treatment of atherosclerotic cardiovascular disease, are beginning to unlock these targets to orally administered therapies to enable broader patient access. We report the convergent biocatalytic assembly of enlicitide from simple building blocks enabled by a suite of engineered enzymes to catalyze selective peptide fragment formation, coupling, and macrocyclization in a protecting group–free manner. Together with efficient crystallizations that obviate the need for chromatography, this approach reduces the number of steps by greater than half compared with prior state-of-the-art methods, addressing long-standing synthetic challenges and offering a sustainable blueprint for the scalable development of complex peptide therapeutics.
- 7 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6798) , 643-647
Top Cited PapersBiocatalytic cascades enable manufacture of the macrocyclic peptide enlicitide
Historically, many compelling therapeutic targets have been accessible only by injectable biologic drugs. Macrocyclic peptides, such as the proprotein convertase subtilisin/kexin type 9 inhibitor enlicitide for the treatment of atherosclerotic cardiovascular disease, are beginning to unlock these targets to orally administered therapies to enable broader patient access. We report the convergent biocatalytic assembly of enlicitide from simple building blocks enabled by a suite of engineered enzymes to catalyze selective peptide fragment formation, coupling, and macrocyclization in a protecting group–free manner. Together with efficient crystallizations that obviate the need for chromatography, this approach reduces the number of steps by greater than half compared with prior state-of-the-art methods, addressing long-standing synthetic challenges and offering a sustainable blueprint for the scalable development of complex peptide therapeutics.
- Open Access
- 16 July 2025
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 5 (7) , 2932-2938
Advancing Biocatalysis Education: Sustaining the Future of Industrial Biotechnology
Industrial biotechnology and biocatalysis are transforming chemical manufacturing by enabling the sustainable production of biobased chemicals, pharmaceuticals, and materials. As these technologies advance, a highly skilled workforce is essential to drive innovation, optimize bioprocesses, and expand industrial applications. Expertise in enzyme engineering, fermentation technology, metabolic pathway optimization, and computational modeling is increasingly critical for developing next-generation biocatalysts and scalable biomanufacturing processes. This viewpoint highlights the growing demand for interdisciplinary training and education in biocatalysis, emphasizing strategies to equip scientists and engineers with the technical competencies needed to sustain progress in the field. By fostering a workforce adept in both fundamental principles and industrial applications, the sector will be well-positioned to accelerate sustainable innovations and meet future challenges in biomanufacturing.
- 16 July 2025
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 5 (7) , 2932-2938
Open AccessAdvancing Biocatalysis Education: Sustaining the Future of Industrial Biotechnology
Industrial biotechnology and biocatalysis are transforming chemical manufacturing by enabling the sustainable production of biobased chemicals, pharmaceuticals, and materials. As these technologies advance, a highly skilled workforce is essential to drive innovation, optimize bioprocesses, and expand industrial applications. Expertise in enzyme engineering, fermentation technology, metabolic pathway optimization, and computational modeling is increasingly critical for developing next-generation biocatalysts and scalable biomanufacturing processes. This viewpoint highlights the growing demand for interdisciplinary training and education in biocatalysis, emphasizing strategies to equip scientists and engineers with the technical competencies needed to sustain progress in the field. By fostering a workforce adept in both fundamental principles and industrial applications, the sector will be well-positioned to accelerate sustainable innovations and meet future challenges in biomanufacturing.
- Open Access
- 9 June 2025
- Published by American Chemical Society (ACS) in ACS Catalysis
- Vol. 15 (12) , 10780-10794
The Evolving Landscape of Industrial Biocatalysis in Perspective from the ACS Green Chemistry Institute Pharmaceutical Roundtable
- 9 June 2025
- Published by American Chemical Society (ACS) in ACS Catalysis
- Vol. 15 (12) , 10780-10794
Open AccessThe Evolving Landscape of Industrial Biocatalysis in Perspective from the ACS Green Chemistry Institute Pharmaceutical Roundtable
- 25 April 2025
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 61 (45) , 8248-8251
Photoenzymatically-induced asymmetric hydroarylation of alkenes with (hetero)aryl halides
(Hetero)aryl halides are established as radical precursors in photoinduced biocatalysis, undergoing asymmetric coupling to alkenes via intermolecular and intramolecular hydroarylation.
- 25 April 2025
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 61 (45) , 8248-8251
Photoenzymatically-induced asymmetric hydroarylation of alkenes with (hetero)aryl halides
(Hetero)aryl halides are established as radical precursors in photoinduced biocatalysis, undergoing asymmetric coupling to alkenes via intermolecular and intramolecular hydroarylation.
- 3 March 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (3) , 920-931
Building Efficient Diastereo- and Enantioselective Synthetic Routes to trans-Cyclopropyl Esters for Rapid Lead Scale-Up
- 3 March 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (3) , 920-931
Building Efficient Diastereo- and Enantioselective Synthetic Routes to trans-Cyclopropyl Esters for Rapid Lead Scale-Up
- 3 February 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (3) , 2147-2182
Synthetic Approaches to the New Drugs Approved during 2023
This review is the next installment of an annual series that discusses the synthetic routes to access 28 small molecule drugs that were approved worldwide in 2023. A brief description of each drug's mechanism of action, the history of its discovery and development, and the synthetic approaches published in primary or patent literature that were most likely used for clinical studies or development are included. Synthetic chemistry, used to convert complex intermediates to active compounds or build a new drug from basic building block chemicals, is critical to delivery of new drugs and treatments for disease to patients.
- 3 February 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (3) , 2147-2182
Synthetic Approaches to the New Drugs Approved during 2023
This review is the next installment of an annual series that discusses the synthetic routes to access 28 small molecule drugs that were approved worldwide in 2023. A brief description of each drug's mechanism of action, the history of its discovery and development, and the synthetic approaches published in primary or patent literature that were most likely used for clinical studies or development are included. Synthetic chemistry, used to convert complex intermediates to active compounds or build a new drug from basic building block chemicals, is critical to delivery of new drugs and treatments for disease to patients.
- Open Access
- 22 January 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Photoenzymatically-Induced Asymmetric Hydroarylation of Alkenes with (Hetero)aryl Halides
Herein we describe a set of privileged and stereocomplementary ene-reductase enzymes which, when induced by light and aided by an exogenous photocatalyst, catalyze the coupling of (hetero)aryl halides and alkenes in an asymmetric intermolecular hydroarylation process. Thus, carbon scaffolds containing C(sp2)-C(sp3) bonds are synthesized enzymatically from simple precursors in excellent enantiomeric excess. Furthermore, an intramolecular coupling is achieved through tethering of (hetero)aryl halides to their alkene reaction partners and in this manner problematic side reactions are suppressed and yields improved. This work extends the utility of photo-induced biocatalysis through the addition of the novel and pharmaceutically important (hetero)aromatic halide class of radical precursors.
- 22 January 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessPhotoenzymatically-Induced Asymmetric Hydroarylation of Alkenes with (Hetero)aryl Halides
Herein we describe a set of privileged and stereocomplementary ene-reductase enzymes which, when induced by light and aided by an exogenous photocatalyst, catalyze the coupling of (hetero)aryl halides and alkenes in an asymmetric intermolecular hydroarylation process. Thus, carbon scaffolds containing C(sp2)-C(sp3) bonds are synthesized enzymatically from simple precursors in excellent enantiomeric excess. Furthermore, an intramolecular coupling is achieved through tethering of (hetero)aryl halides to their alkene reaction partners and in this manner problematic side reactions are suppressed and yields improved. This work extends the utility of photo-induced biocatalysis through the addition of the novel and pharmaceutically important (hetero)aromatic halide class of radical precursors.
- 9 December 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (24) , 22002-22038
Discovery of PF-07265028, A Selective Small Molecule Inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) for the Treatment of Cancer
Hematopoietic progenitor kinase 1 (HPK1/MAP4K1) represents a high interest target for the treatment of cancer through an immune-mediated mechanism. Herein we present highlights of the drug discovery campaign within the lactam/azalactam series of inhibitors that yielded a small molecule (21, PF-07265028), which was advanced to a phase 1 clinical trial (NCT05233436). Key components of the discovery effort included optimization of potency through mitigation of ligand strain as guided by the use of cocrystal structures, mitigation of ADME liabilities (plasma instability and fraction metabolism by CYP2D6), and optimization of kinase selectivity, particularly over immune-modulating kinases with high homology to HPK1. Structure-based drug design via leveraging cocrystal structures and lipophilic efficiency analysis proved to be valuable tools that ultimately enabled the delivery of a clinical-quality small molecule inhibitor of HPK1.
- 9 December 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (24) , 22002-22038
Discovery of PF-07265028, A Selective Small Molecule Inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) for the Treatment of Cancer
Hematopoietic progenitor kinase 1 (HPK1/MAP4K1) represents a high interest target for the treatment of cancer through an immune-mediated mechanism. Herein we present highlights of the drug discovery campaign within the lactam/azalactam series of inhibitors that yielded a small molecule (21, PF-07265028), which was advanced to a phase 1 clinical trial (NCT05233436). Key components of the discovery effort included optimization of potency through mitigation of ligand strain as guided by the use of cocrystal structures, mitigation of ADME liabilities (plasma instability and fraction metabolism by CYP2D6), and optimization of kinase selectivity, particularly over immune-modulating kinases with high homology to HPK1. Structure-based drug design via leveraging cocrystal structures and lipophilic efficiency analysis proved to be valuable tools that ultimately enabled the delivery of a clinical-quality small molecule inhibitor of HPK1.
- 15 March 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (6) , 4376-4418
Synthetic Approaches to the New Drugs Approved During 2022
In 2022, 23 new small molecule chemical entities were approved as drugs by the United States FDA, European Union EMA, Japan PMDA, and China NMPA. This review describes the synthetic approach demonstrated on largest scale for each new drug based on patent or primary literature. The synthetic routes highlight practical methods to construct molecules, sometimes on the manufacturing scale, to access the new drugs. Ten additional drugs approved in 2021 and one approved in 2020 are included that were not covered in the previous year's review.
- 15 March 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (6) , 4376-4418
Synthetic Approaches to the New Drugs Approved During 2022
In 2022, 23 new small molecule chemical entities were approved as drugs by the United States FDA, European Union EMA, Japan PMDA, and China NMPA. This review describes the synthetic approach demonstrated on largest scale for each new drug based on patent or primary literature. The synthetic routes highlight practical methods to construct molecules, sometimes on the manufacturing scale, to access the new drugs. Ten additional drugs approved in 2021 and one approved in 2020 are included that were not covered in the previous year's review.